0.578
1.40%
0.008
Bolt Biotherapeutics Inc stock is traded at $0.578, with a volume of 11,252.
It is up +1.40% in the last 24 hours and down -9.35% over the past month.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
See More
Previous Close:
$0.57
Open:
$0.5655
24h Volume:
11,252
Relative Volume:
0.08
Market Cap:
$22.15M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-0.2833
EPS:
-2.04
Net Cash Flow:
$-69.73M
1W Performance:
-7.13%
1M Performance:
-9.35%
6M Performance:
-25.42%
1Y Performance:
-33.18%
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650-665-9295
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
BOLT | 0.578 | 22.15M | 7.88M | -69.20M | -69.73M | -2.04 |
VRTX | 448.66 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.45 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 588.56 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.89 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.27 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mar-02-21 | Initiated | Guggenheim | Buy |
Mar-02-21 | Initiated | Morgan Stanley | Overweight |
Mar-02-21 | Initiated | SVB Leerink | Outperform |
Mar-02-21 | Initiated | Stifel | Buy |
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
Bolt Biotherapeutics stock hits 52-week low at $0.54 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.54 - Investing.com
HC Wainwright Issues Pessimistic Forecast for BOLT Earnings - Defense World
Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look - TipRanks
Bolt Biotherapeutics Reports Q3 2024 Financial Results - TipRanks
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot - Houston Chronicle
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation - Yahoo Finance
BOLTBolt Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting - The Manila Times
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Marketscreener.com
Bolt Biotherapeutics (STU:6LP) Cash Flow from Investing : €52.47 Mil (TTM As of Jun. 2024) - GuruFocus.com
Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
BOLT Stock Surges Over 5% Amidst Biotech Sector's Mixed Performa - GuruFocus.com
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline
Bolt Biotherapeutics (BOLT) Stock Surges Amid Broad Biotech Indu - GuruFocus.com
Renaissance Technologies LLC Sells 240,898 Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) - Defense World
Renaissance Technologies LLC Has $208,000 Stock Holdings in Hesai Group (NASDAQ:HSAI) - Defense World
Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Drops By 39.1% - Defense World
Just Auto Excellence Awards 2024: TomTom - just-auto.com
Bolt Biotherapeutics (BOLT) Stock Surges Amid Biotech Sector Vol - GuruFocus.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 14.2% in September - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.61 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.61 - Investing.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Decrease in Short Interest - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.65 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.65 - Investing.com
Bolt Biotherapeutics Announces Changes to its Board of Directors - ForexTV.com
Bolt Biotherapeutics reshuffles board, appoints new chair By Investing.com - Investing.com Canada
Bolt Biotherapeutics reshuffles board, appoints new director - Investing.com
Bolt Biotherapeutics Announces Board Reshuffle and New Appointment - TipRanks
Deadline on Sept. 3rd coming up in Lawsuit for Investors in shares of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) - openPR
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesBOLT - PR Newswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the - EIN News
BOLT Investors Have the Opportunity to Lead Bolt - GlobeNewswire
BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt - The Malaysian Reserve
BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
BOLT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Finansavisen - Finansavisen
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):